Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Long-term Debt
Borrowings due after more than one year.
Benitec Biopharma Inc.NASDAQ: BNTC
Long-term Debt · Q3 FY2026 · quarter ended Mar 2026
Long-term debt remains negative
Q3 FY2026 long-term debt was $394K, compared with $0 a year earlier.
Context
- Long-term debt amounted to 0.2% of total assets at the end of Q3 FY2026, up 0.2 pp from a year earlier.
- Long-term debt increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Long-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | — |
| FY2023 | 2023-06-30 | 0 | — |
| FY2022 | 2022-06-30 | 0 | — |
| FY2021 | 2021-06-30 | 0 | — |
Long-term Debt vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 long-term debt of $394K is the 6th highest of the 10 companies compared; the peer median is $6.08M.
- Long-term debt amounts to 0.2% of total assets for BNTC, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $135.71M | +1155.1% | +49.7% | 861.2% | |
| Mar 2026 | $88.83M | -11.1% | — | 32.7% | |
| Mar 2026 | $76.9M | -69.7% | — | 14.6% | |
| Mar 2026 | $24.19M | -12.6% | +129.1% | 42.5% | |
| Mar 2026 | $6.08M | — | — | 2.3% | |
| Mar 2026 | $394K | — | — | 0.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BNTC) | $6.08M | -11.8% | +89.4% | 2.3% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.